The Filings Report

Humana Inc.

HUMNYSECIK 49071Healthcare / Healthcare Plansfiscal year ends December72 quarters since 2008

Revenue, Q1 FY2026
$39.6B
+23.5% on Q1 FY2025
Net income
$1.2B
no year-earlier figure
Free cash flow
$1.1B
+380.1% on Q1 FY2025
Diluted EPS
$9.83
−4.6% on Q1 FY2025
Revenue, TTM
$137.2B
trailing four quarters
Net margin, TTM
0.8%
net income $1.1B
Free cash flow, TTM
$1.3B
$1.8B less $572M capex
Cash and equivalents
$5.0B
long-term debt $12.3B, Mar 31, 2026
Shares, 12-month change
−0.5%
120M shares, Mar 31, 2026
Buybacks, TTM
$249M
0.5% of market value
Dividends, TTM
$429M
0.9% of market value
Market value
$49.8B
at the close, buybacks

Latest quarter Q1 FY2026, filed April 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q1 FY2026, the quarter ended March 31, 2026, Humana Inc. reported revenue of $39.6B, +23.5% on Q1 FY2025, and net income of $1.2B. Operating margin was 4.4%. Free cash flow, operating cash flow less capital expenditures, was $1.1B ($1.3B less $121M). Diluted earnings per share were $9.83.

The last 16 quarters

Q2 FY2022 to Q1 FY2026, through the filing of April 29, 2026.

Revenue and net incomeRevenueNet income
−$20B$0$20B$40BQ2'22, Revenue: $23.7BQ2'22, Net income: $696MQ2'22Q3'22, Revenue: $22.8BQ3'22, Net income: $1.2BQ3'22Q4'22, Revenue: $22.4BQ4'22, Net income: −$15MQ4'22Q1'23, Revenue: $26.7BQ1'23, Net income: $1.2BQ1'23Q2'23, Revenue: $26.7BQ2'23, Net income: $959MQ2'23Q3'23, Revenue: $26.4BQ3'23, Net income: $832MQ3'23Q4'23, Revenue: $26.5BQ4'23, Net income: −$541MQ4'23Q1'24, Revenue: $29.6BQ1'24, Net income: $741MQ1'24Q2'24, Revenue: $29.5BQ2'24, Net income: $679MQ2'24Q3'24, Revenue: $29.4BQ3'24, Net income: $480MQ3'24Q4'24, Revenue: $29.2BQ4'24, Net income: −$693MQ4'24Q1'25, Revenue: $32.1BQ1'25Q2'25, Revenue: $32.4BQ2'25, Net income: $545MQ2'25Q3'25, Revenue: $32.6BQ3'25, Net income: $195MQ3'25Q4'25, Revenue: $32.5BQ4'25, Net income: −$796MQ4'25Q1'26, Revenue: $39.6BQ1'26, Net income: $1.2BQ1'26−$20B$0$20B$40BQ2'22, Revenue: $23.7BQ2'22, Net income: $696MQ3'22, Revenue: $22.8BQ3'22, Net income: $1.2BQ3'22Q4'22, Revenue: $22.4BQ4'22, Net income: −$15MQ1'23, Revenue: $26.7BQ1'23, Net income: $1.2BQ1'23Q2'23, Revenue: $26.7BQ2'23, Net income: $959MQ3'23, Revenue: $26.4BQ3'23, Net income: $832MQ3'23Q4'23, Revenue: $26.5BQ4'23, Net income: −$541MQ1'24, Revenue: $29.6BQ1'24, Net income: $741MQ1'24Q2'24, Revenue: $29.5BQ2'24, Net income: $679MQ3'24, Revenue: $29.4BQ3'24, Net income: $480MQ3'24Q4'24, Revenue: $29.2BQ4'24, Net income: −$693MQ1'25, Revenue: $32.1BQ1'25Q2'25, Revenue: $32.4BQ2'25, Net income: $545MQ3'25, Revenue: $32.6BQ3'25, Net income: $195MQ3'25Q4'25, Revenue: $32.5BQ4'25, Net income: −$796MQ1'26, Revenue: $39.6BQ1'26, Net income: $1.2BQ1'26

Net income losses drawn in red.

Free cash flow
−$10B−$5B$0$5B$10BQ2'22, Free cash flow: $680MQ2'22Q3'22, Free cash flow: $8.2BQ3'22Q4'22, Free cash flow: −$5.4BQ4'22Q1'23, Free cash flow: $6.5BQ1'23Q2'23, Free cash flow: $2.9BQ2'23Q3'23, Free cash flow: $1.0BQ3'23Q4'23, Free cash flow: −$7.4BQ4'23Q1'24, Free cash flow: $246MQ1'24Q2'24, Free cash flow: $1.1BQ2'24Q3'24, Free cash flow: $1.7BQ3'24Q4'24, Free cash flow: −$682MQ4'24Q1'25, Free cash flow: $236MQ1'25Q2'25, Free cash flow: $1.2BQ2'25Q3'25, Free cash flow: $836MQ3'25Q4'25, Free cash flow: −$1.9BQ4'25Q1'26, Free cash flow: $1.1BQ1'26−$10B−$5B$0$5B$10BQ2'22, Free cash flow: $680MQ3'22, Free cash flow: $8.2BQ3'22Q4'22, Free cash flow: −$5.4BQ1'23, Free cash flow: $6.5BQ1'23Q2'23, Free cash flow: $2.9BQ3'23, Free cash flow: $1.0BQ3'23Q4'23, Free cash flow: −$7.4BQ1'24, Free cash flow: $246MQ1'24Q2'24, Free cash flow: $1.1BQ3'24, Free cash flow: $1.7BQ3'24Q4'24, Free cash flow: −$682MQ1'25, Free cash flow: $236MQ1'25Q2'25, Free cash flow: $1.2BQ3'25, Free cash flow: $836MQ3'25Q4'25, Free cash flow: −$1.9BQ1'26, Free cash flow: $1.1BQ1'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15B$20BQ2'22, Cash and equivalents: $5.2BQ2'22, Long-term debt: $11.3BQ2'22Q3'22, Cash and equivalents: $13.6BQ3'22, Long-term debt: $7.8BQ3'22Q4'22, Cash and equivalents: $5.1BQ4'22, Long-term debt: $9.0BQ4'22Q1'23, Cash and equivalents: $13.7BQ1'23, Long-term debt: $9.7BQ1'23Q2'23, Cash and equivalents: $16.2BQ2'23, Long-term debt: $9.7BQ2'23Q3'23, Cash and equivalents: $15.1BQ3'23, Long-term debt: $9.5BQ3'23Q4'23, Cash and equivalents: $4.7BQ4'23, Long-term debt: $10.2BQ4'23Q1'24, Cash and equivalents: $5.9BQ1'24, Long-term debt: $12.4BQ1'24Q2'24, Cash and equivalents: $5.5BQ2'24, Long-term debt: $11.7BQ2'24Q3'24, Cash and equivalents: $5.1BQ3'24, Long-term debt: $11.9BQ3'24Q4'24, Cash and equivalents: $2.2BQ4'24, Long-term debt: $11.1BQ4'24Q1'25, Cash and equivalents: $4.3BQ1'25, Long-term debt: $12.7BQ1'25Q2'25, Cash and equivalents: $4.0BQ2'25, Long-term debt: $12.6BQ2'25Q3'25, Cash and equivalents: $5.4BQ3'25, Long-term debt: $12.6BQ3'25Q4'25, Cash and equivalents: $4.2BQ4'25, Long-term debt: $12.4BQ4'25Q1'26, Cash and equivalents: $5.0BQ1'26, Long-term debt: $12.3BQ1'26$0$5B$10B$15B$20BQ2'22, Cash and equivalents: $5.2BQ2'22, Long-term debt: $11.3BQ3'22, Cash and equivalents: $13.6BQ3'22, Long-term debt: $7.8BQ3'22Q4'22, Cash and equivalents: $5.1BQ4'22, Long-term debt: $9.0BQ1'23, Cash and equivalents: $13.7BQ1'23, Long-term debt: $9.7BQ1'23Q2'23, Cash and equivalents: $16.2BQ2'23, Long-term debt: $9.7BQ3'23, Cash and equivalents: $15.1BQ3'23, Long-term debt: $9.5BQ3'23Q4'23, Cash and equivalents: $4.7BQ4'23, Long-term debt: $10.2BQ1'24, Cash and equivalents: $5.9BQ1'24, Long-term debt: $12.4BQ1'24Q2'24, Cash and equivalents: $5.5BQ2'24, Long-term debt: $11.7BQ3'24, Cash and equivalents: $5.1BQ3'24, Long-term debt: $11.9BQ3'24Q4'24, Cash and equivalents: $2.2BQ4'24, Long-term debt: $11.1BQ1'25, Cash and equivalents: $4.3BQ1'25, Long-term debt: $12.7BQ1'25Q2'25, Cash and equivalents: $4.0BQ2'25, Long-term debt: $12.6BQ3'25, Cash and equivalents: $5.4BQ3'25, Long-term debt: $12.6BQ3'25Q4'25, Cash and equivalents: $4.2BQ4'25, Long-term debt: $12.4BQ1'26, Cash and equivalents: $5.0BQ1'26, Long-term debt: $12.3BQ1'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Humana Inc. income statement, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Revenue39,64832,51532,64932,38832,11229,21329,39729,540+23.5%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative4,0244,4384,0853,5473,3804,1673,3393,148+19.1%
Operating income1,754(808)4001,0982,014(543)7281,141−12.9%
Other income (expense)34(53)(35)(200)(163)(155)92(55)+120.9%
Pretax income1,595(1,128)134741—(963)651918—
Income tax395(249)(86)179406(216)155223−2.7%
Net income1,186(796)195545—(693)480679—
Diluted EPS ($)9.83—1.624.5110.30—3.985.62−4.6%
Diluted shares (millions)121—121121121—121121—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Humana Inc. balance sheet, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Cash and equivalents4,9514,2005,3884,0404,2502,2215,1165,501+16.5%
Short-term investments17,01415,70316,73617,66817,88818,21419,03317,424−4.9%
Total current assets38,08032,73332,75233,61534,42229,81532,92632,858+10.6%
Total assets55,28048,90949,71950,35750,93046,47950,00750,093+8.5%
Total current liabilities21,50716,34616,18017,21918,04316,93918,72719,790+19.2%
Long-term debt12,27412,36912,60712,58612,72911,14411,88611,746−3.6%
Total liabilities36,63431,17231,13732,06233,11130,03432,38333,365+10.6%
Stockholders’ equity18,58017,65718,52218,23417,75116,37517,56516,671+4.7%
Shares outstanding (millions)120121120120121121120120—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q1 FY2026 filed April 29, 2026.

Humana Inc. cash flow statement, quarterly
Millions of dollarsQ1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024Q2 FY2024ended Jun 30, 2024filed Jul 31, 2024YoYQ1 FY2026vs Q1 FY2025
Operating cash flow1,254(1,652)9711,271331(528)1,8581,213+278.9%
Capital expenditures12120213511495154130114+27.4%
Free cash flow (CFO − capex)1,133(1,854)8361,157236(682)1,7281,099+380.1%
Depreciation and amortization163164173178183208210212−10.9%
Share repurchases107420100949249+1088.9%
Dividends paid107109107106108108107107−0.9%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 19, 2026.

Income statement

Humana Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 18, 2016FY2014ended Dec 31, 2014filed Feb 18, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 3, 2009FY2007ended Dec 31, 2007filed Aug 3, 2009
Revenue129,664117,761106,37492,87083,06477,15564,88856,91253,76754,37954,28948,50041,31339,12636,83233,59630,74328,94625,290
Cost of revenue———————————————————
Gross profit———————————————————
Research and development———————————————————
Selling, general and administrative15,45013,69613,18812,67110,12110,0527,3817,5256,5677,1737,2957,6396,3555,8305,3954,3804,0143,9453,476
Operating income2,7042,5624,0133,8003,1484,9863,1923,1004,2621,7412,3472,3622,0612,0162,3441,8541,7081,0731,358
Other income (expense)(451)(181)(137)(68)532(103)506(33)00—————————
Pretax income1,4381,6203,3253,5683,4194,6743,4702,0744,0201,5522,4312,1701,9211,9112,2351,7491,6029931,289
Income tax2504138367624851,3077633911,5729381,1551,023690689816650562346456
Net income1,1881,2072,4892,8062,9333,3672,7071,6832,4486141,2761,1471,2311,2221,4191,0991,040647834
Diluted EPS ($)9.849.9820.0022.0822.6725.3120.1012.1616.814.078.447.367.737.478.466.476.153.834.91
Diluted shares (millions)121121124127129133135138146151151156159163168170169169—

Balance sheet

Humana Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 18, 2016FY2014ended Dec 31, 2014filed Feb 18, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 3, 2009FY2007ended Dec 31, 2007filed Aug 3, 2009
Cash and equivalents4,2002,2214,6945,0613,3944,6734,0542,3434,0423,8772,5711,9351,1381,3061,3771,6731,6131,9702,040
Short-term investments15,70318,21416,62613,88113,19212,55410,97210,0269,5577,5957,2677,5988,0908,0017,7436,8736,1904,204—
Total current assets32,73329,81529,98626,18324,89323,64119,88816,94817,40216,19015,71115,53612,30011,71011,18110,1379,2538,396—
Total assets48,90946,47947,06543,05544,35834,96929,07425,41327,17825,39624,67823,52720,73519,97917,70816,10314,15313,042—
Total current liabilities16,34616,93918,87217,17815,33113,39410,92910,0779,4067,8228,1527,4716,3236,3756,0565,7445,2605,184—
Long-term debt12,36911,14410,2139,03410,5416,0604,9674,3754,7703,7923,7943,8252,6002,6111,6591,6691,6781,937—
Total liabilities31,17230,03430,74727,68528,25521,24117,03715,25217,33614,71114,33213,88111,41911,1329,6459,1798,3778,585—
Stockholders’ equity17,65716,37516,26215,31116,08013,72812,03710,1619,84210,68510,3469,6469,3168,8478,0636,9245,7764,4574,029
Shares outstanding (millions)121121121125127129132136138149148150154158164169170——

Cash flow statement

Humana Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 20, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 18, 2016FY2014ended Dec 31, 2014filed Feb 18, 2015FY2013ended Dec 31, 2013filed Feb 19, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 19, 2010FY2008ended Dec 31, 2008filed Aug 3, 2009FY2007ended Dec 31, 2007filed Aug 3, 2009
Operating cash flow9212,9663,9814,5872,2625,6395,2842,1734,0511,9368681,6181,7161,9232,0792,2421,4229821,224
Capital expenditures5465751,0041,1371,342964736612524527523528441410346222185262239
Free cash flow (CFO − capex)3752,3912,9773,4509204,6754,5481,5613,5271,4093451,0901,2751,5131,7332,0201,237721985
Depreciation and amortization698839779709596——444410388354328309338303263250220185
Share repurchases1518171,5732,096791,8201,0701,0903,3651043858725315185411082310627
Dividends paid4304314313923543232912652201771721721681658200——

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$150K
1 purchases by 1 insider; officers and directors $150K
Sold, twelve months
$0
0 sales by 0 insiders; officers and directors $0

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 1, 2026Nundy ShantanuChief Medical Officeraward2,549$0.00—2,549Sep 3, 2026
Aug 1, 2026Smith Paul JohnDirectoraward544$0.00—544Aug 4, 2026
Aug 1, 2026Crawford Frederick JohnDirectoraward544$0.00—544Aug 4, 2026
May 1, 2026Mellet CelesteChief Financial Officeraward15,387$0.00—39,637May 5, 2026
May 1, 2026Mehta JapanChief Information Officeraward9,448$0.00—17,176May 5, 2026
May 1, 2026Dintenfass DavidPresident, Enterprise Growthaward11,273$0.00—25,407May 5, 2026
May 1, 2026Rechtin James A.President & CEOawardindirect35,633$0.00—63,938May 5, 2026
May 1, 2026O'Hara Michelle A.Chief Human Resources Officeraward10,485$0.00—20,026May 5, 2026
May 1, 2026Field Robert StuartDirectoraward852$0.00—852May 5, 2026
May 1, 2026Ventura Joseph CChief Legal Officeraward10,318$0.00—27,405May 5, 2026
May 1, 2026Shetty Sanjay KPresident, CenterWellaward9,945$0.00—22,088May 5, 2026
May 1, 2026Martin AaronPresident, Medicare Advantageaward8,206$0.00—25,237May 5, 2026
Apr 1, 2026Shetty Sanjay KPresident, CenterWelloption exercise887$0.00—12,544Apr 3, 2026
Apr 1, 2026Shetty Sanjay KPresident, CenterWelltax withholding401$175.44$70K12,143Apr 3, 2026
Feb 24, 2026Ventura Joseph CChief Legal Officeroption exercise1,035$0.00—17,565Feb 26, 2026
Feb 24, 2026Ventura Joseph CChief Legal Officertax withholding478$177.08$85K17,087Feb 26, 2026
Feb 24, 2026Renaudin George IIPresident, Insuranceoption exercise1,035$0.00—16,494Feb 26, 2026
Feb 24, 2026Renaudin George IIPresident, Insurancetax withholding419$177.08$74K16,075Feb 26, 2026
Feb 24, 2026Felter John-Paul W.SVP, Chief Accting Off & Cont.option exercise165$0.00—7,568Feb 25, 2026
Feb 24, 2026Felter John-Paul W.SVP, Chief Accting Off & Cont.tax withholding84$177.08$15K7,484Feb 25, 2026
Feb 23, 2026Felter John-Paul W.SVP, Chief Accting Off & Cont.award5,669$0.00—7,403Feb 25, 2026
Feb 23, 2026Shetty Sanjay KPresident, CenterWellopen-market buy810$185.21$150K11,657Feb 25, 2026
Feb 21, 2026Dintenfass DavidPresident, Enterprise Growthoption exercise3,858$0.00—15,316Feb 24, 2026
Feb 21, 2026Dintenfass DavidPresident, Enterprise Growthtax withholding1,182$189.66$224K14,134Feb 24, 2026
Feb 13, 2026Mehta JapanChief Information Officeroption exercise1,682$0.00—8,158Feb 18, 2026

Full insider history for Humana Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
HUMANA INC, CIK 49071 on EDGAR
Extract generated
October 6, 2026
Withheld
none
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2025, pretax income FY2025
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 6, 2026.

JSON file
/data/financials/HUM.json